Psychological Impact of Amenorrhea in Women With Endometriosis

NCT ID: NCT02393482

Last Updated: 2021-02-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-06-30

Study Completion Date

2022-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to evaluate the impact on quality of life, psychological health, sexuality and chronic pain of therapies which determine amenorrhea in symptomatic women with endometriosis, through the administration of self reported questionnaires. Amenorrhea in the first group is caused by balanced assumption of estroprogestins, in the second group is caused by GnRHa-induced hypoestrogenism.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Amenorrhea Endometriosis Quality of Life

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Balanced estroprogestins

Women assigned to this arm will assume balanced monophasic estroprogestins (etinil-estradiol 100 mcg/levonorgestrel 20 mcg), one tablet orally daily, for 180 days.

Group Type ACTIVE_COMPARATOR

Estroprogestinic therapy (Etinil-estradiol/levonorgestre)

Intervention Type DRUG

Etinil-estradiol/levonorgestrel (100 mcg/20 mcg)/die

GnRHa

Women assigned to this arm will assume Leuprorelin acetate (3,75 mg/2ml), one intramuscular administration every 28 days. After 45 days of treatment, therapy will be implemented with Tibolone 5 mg, one tablet daily orally, and Calcium carbonate/colecalciferol (500 mg/400 UI), one tablet daily orally. This therapy will be prosecuted for the remaining 135 days of treatment.

Group Type ACTIVE_COMPARATOR

Gonadotropin-releasing hormone agonist (Leuprorelin acetate)

Intervention Type DRUG

Leuprorelin acetate (3,75 mg/2 ml)/month

Add back therapy 1 (tibolone)

Intervention Type DRUG

tibolone 5 mg/die

Add back therapy 2 (calcium carbonate/colecalciferol)

Intervention Type DRUG

calcium carbonate/colecalciferol (500mg/400UI)/die

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Estroprogestinic therapy (Etinil-estradiol/levonorgestre)

Etinil-estradiol/levonorgestrel (100 mcg/20 mcg)/die

Intervention Type DRUG

Gonadotropin-releasing hormone agonist (Leuprorelin acetate)

Leuprorelin acetate (3,75 mg/2 ml)/month

Intervention Type DRUG

Add back therapy 1 (tibolone)

tibolone 5 mg/die

Intervention Type DRUG

Add back therapy 2 (calcium carbonate/colecalciferol)

calcium carbonate/colecalciferol (500mg/400UI)/die

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical, echographical or surgical diagnosis of endometriosis

Exclusion Criteria

* Comorbidity
* Psychiatric diseases
* Refusal or inability to sign informed consent
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Cagliari

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Stefano Angioni

MD,PhD

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Cagliari,Obstetrics and Gynecological Department,

Monserrato, Cagliari, Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

References

Explore related publications, articles, or registry entries linked to this study.

McWilliams LA, Cox BJ, Enns MW. Mood and anxiety disorders associated with chronic pain: an examination in a nationally representative sample. Pain. 2003 Nov;106(1-2):127-33. doi: 10.1016/s0304-3959(03)00301-4.

Reference Type BACKGROUND
PMID: 14581119 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AMENORREA

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Endometriosis and Pain
NCT03993197 COMPLETED NA